Paper11041565
Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
Baker KS and 5 others. Bone Marrow Transplant, 2000. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Papers, record 11041565. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11041565
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Alkylating | Major topic |
| Busulfan | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Immunosuppressive Agents | Major topic |
| Leukemia, Myeloid | Major topic |
| Acute Disease | |
| Adolescent | |
| Adult | |
| Child | |
| Child, Preschool | |
| Combined Modality Therapy | |
| Disease-Free Survival | |
| Female | |
| Graft vs Host Disease | |
| Humans | |
| Infant | |
| Male | |
| Middle Aged | |
| Remission Induction | |
| Survival Rate | |
| Transplantation Conditioning |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8269597 | Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8269597 | PubMed |
| 2 | 2591002 | Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2591002 | PubMed |
| 3 | 7803883 | Busulfan. | Ann Pharmacother | 1994 | https://conductscience.org/library/papers/7803883 | PubMed |
| 4 | 7919328 | Busulfan bioavailability. | Blood | 1994 | https://conductscience.org/library/papers/7919328 | PubMed |
| 5 | 8882952 | Aspects concerning busulfan pharmacokinetics and bioavailability. | Leuk Lymphoma | 1996 | https://conductscience.org/library/papers/8882952 | PubMed |
| 6 | 7581127 | Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. | Bone Marrow Transplant | 1995 | https://conductscience.org/library/papers/7581127 | PubMed |
| 7 | 9196136 | Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. | J Clin Oncol | 1997 | https://conductscience.org/library/papers/9196136 | PubMed |
| 8 | 18820 | Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients. | Transplantation | 1977 | https://conductscience.org/library/papers/18820 | PubMed |
| 9 | 1571560 | Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? | Blood | 1992 | https://conductscience.org/library/papers/1571560 | PubMed |
| 10 | 6372650 | Graft-versus-host disease: pathophysiological and clinical aspects. | Annu Rev Med | 1984 | https://conductscience.org/library/papers/6372650 | PubMed |
| 11 | 2861312 | Marrow transplantation for thalassaemia following busulphan and cyclophosphamide. | Lancet | 1985 | https://conductscience.org/library/papers/2861312 | PubMed |
| 12 | 8932835 | Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. | Bone Marrow Transplant | 1996 | https://conductscience.org/library/papers/8932835 | PubMed |
| 13 | 2060084 | Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/2060084 | PubMed |
| 14 | 8712747 | Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). | Anticancer Res | 1996 | https://conductscience.org/library/papers/8712747 | PubMed |
| 15 | 1421415 | Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. | Blood | 1992 | https://conductscience.org/library/papers/1421415 | PubMed |
| 16 | 9028555 | Growth after bone marrow transplantation in young children conditioned with chemotherapy alone. | Bone Marrow Transplant | 1997 | https://conductscience.org/library/papers/9028555 | PubMed |
| 17 | 8338934 | Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. | Blood | 1993 | https://conductscience.org/library/papers/8338934 | PubMed |
| 18 | 2791192 | Pharmacokinetics of high-dose busulfan in children. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2791192 | PubMed |
| 19 | 8888742 | Growth in children undergoing bone marrow transplantation after busulfan and cyclophosphamide conditioning. | J Pediatr Hematol Oncol | 1996 | https://conductscience.org/library/papers/8888742 | PubMed |
| 20 | 2328321 | Busulfan disposition in children. | Blood | 1990 | https://conductscience.org/library/papers/2328321 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35784763 | The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35784763 | PubMed |
| 34956984 | Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia. | Front Pediatr | 2021 | https://conductscience.org/library/papers/34956984 | PubMed |
| 31578451 | Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. | Leukemia | 2020 | https://conductscience.org/library/papers/31578451 | PubMed |
| 29608607 | Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children. | PLoS One | 2018 | https://conductscience.org/library/papers/29608607 | PubMed |
| 29207608 | GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. | Oncotarget | 2017 | https://conductscience.org/library/papers/29207608 | PubMed |
| 25347008 | Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics. | Bone Marrow Transplant | 2015 | https://conductscience.org/library/papers/25347008 | PubMed |
| 23444282 | Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. | J Clin Pharmacol | 2013 | https://conductscience.org/library/papers/23444282 | PubMed |
| 15480668 | Autologous stem cell transplantation in hematological malignancies. | Springer Semin Immunopathol | 2004 | https://conductscience.org/library/papers/15480668 | PubMed |
| 15195074 | Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages. | Bone Marrow Transplant | 2004 | https://conductscience.org/library/papers/15195074 | PubMed |
| 13130310 | Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. | Bone Marrow Transplant | 2003 | https://conductscience.org/library/papers/13130310 | PubMed |
| 12953124 | Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. | Bone Marrow Transplant | 2003 | https://conductscience.org/library/papers/12953124 | PubMed |
| 12189535 | Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. | Bone Marrow Transplant | 2002 | https://conductscience.org/library/papers/12189535 | PubMed |
| 11781625 | Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. | Bone Marrow Transplant | 2001 | https://conductscience.org/library/papers/11781625 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11041565
GET https://conductscience.org/api/papers/v1/11041565/references?page=2